
|Articles|January 1, 2003
No consensus: Clinical trials wrestle with role of atropine in treating amblyopia
Author(s)Laura Newman, MD
Baltimore-Amblyopia is a relatively common problem in children, but there is no consensus on the best treatment. Recently, there has been increasing interest in using atropine drops instead of patching, but they are not FDA approved for that indication, said Michael X. Repka, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
FDA approvals in 2025: What changed and why it matters for ophthalmologists
3
PRIMAvera study: Central vision improvement with subretinal implant
4
What changed in glaucoma care in 2025: Surgeon perspective
5












































